Infineon v Innoscience: What the Gallium Nitride Patent Fight Reveals About Chinese IP Enforcement
Hookway, Paige. “Infineon Vs. Innoscience: The GaN Patent War.” Electronic Specifier, 15 June 2026, www.electronicspecifier.com/news/analysis/infineon-vs-innoscience-the-gan-patent-war/.
On 13 June 2026, Chinese semiconductor company Innoscience announced what it described as its “final victory in China” over German chipmaker Infineon. China’s Supreme People’s Court (SPC) had maintained restrictions on the sale of certain Infineon gallium nitride (GaN) products following proceedings brought by Innoscience in Suzhou. Three days later, however, Infineon disputed that characterisation, arguing that the ruling concerned preliminary relief, that the main proceedings remained ongoing, and that the practical effect on its GaN business would be limited. When the SPC’s decisions were subsequently published, they confirmed that the measures were interim rather than final determinations on the merits.
The dispute raises a question that extends beyond the two companies: when a foreign company loses a patent ruling in China, how much does that outcome tell us about the treatment of foreign litigants by Chinese courts? By reviewing existing empirical research alongside the Infineon–Innoscience dispute, this article argues that an adverse ruling, without more, is not sufficient evidence of anti-foreign judicial bias. The available evidence does not establish that China’s intellectual property system is free of problems; it does, however, make broad conclusions based on a single case difficult to sustain.
The wider debate about Chinese IP enforcement
Patent litigation is rarely confined to a single lawsuit or legal system. Patents are territorial rights: a patent granted in one jurisdiction does not automatically confer equivalent rights elsewhere. Companies competing internationally may therefore pursue separate infringement proceedings in each jurisdiction in which the disputed products are manufactured, imported or sold. One commercial conflict can consequently generate multiple lawsuits involving different patents, procedural rules and remedies, producing outcomes which appear inconsistent while addressing legally distinct questions.
Concerns about China's intellectual property regime nevertheless remain prominent in international trade policy. The Office of the United States Trade Representative's 2026 Special 301 Report, issued as part of its annual review under section 182 of the Trade Act of 1974, again placed China on its Priority Watch List. The report identifies continuing concerns surrounding technology transfer, trade secrets, counterfeiting, piracy, and patent policy, and expressly questions whether intellectual property protection and enforcement operate fairly for foreign right holders. China was one of six countries placed on the Priority Watch List in 2026 following USTR's review of more than 100 trading partners. However, the Special 301 Report addresses a broad range of issues and China’s inclusion does not, by itself, demonstrate that Chinese courts decide individual patent disputes on the basis of a litigant’s nationality.
That distinction matters. Concerns about forced technology transfer, counterfeiting, or state industrial policy should not be dismissed, but they are not interchangeable with empirical evidence that foreign companies are systematically disadvantaged in civil patent litigation. To assess that narrower claim, it is necessary to examine case outcomes and consider what the underlying data can – and cannot – show.
What the empirical evidence shows
A 2025 review by intellectual property firm Spruson and Ferguson, drawing on statistics released by Chinese courts, reported that Beijing's Chaoyang District court adjudicated 117 cases between 2014 and 2022 in which foreign litigants sued domestic entities. Foreign plaintiffs succeeded in approximately 77 per cent of those cases. The review also reported Beijing IP Court data showing that, excluding disputes solely between foreign parties, foreign litigants succeeded in approximately 68 per cent of foreign-related IP cases. In civil claims, foreign plaintiffs recorded higher success rates than plaintiffs in litigation involving only Chinese parties.
Earlier litigation data point in a similar direction. The China Intellectual Property Litigation Analysis (CIELA) database reported an 87 per cent first-instance win rate for foreign plaintiffs in patent infringement cases during the period covered by its research. This figure should be kept distinct from CIELA's separate finding that foreign plaintiffs won 85.3 per cent of software copyright cases in its dataset, as that statistic concerns copyright litigation rather than patents.
Academic research has also challenged the assumption that China's patent courts operate primarily as instruments of local protectionism. A study by Brian Love, Christine Helmers and Markus Eberhardt examined patent litigation between 2006 and 2011 across the fifty Chinese courts with the most active intellectual property dockets. It found that patent litigation was heavily concentrated in major urban jurisdictions rather than the smaller inland courts where local protectionism was often thought most likely to arise. Foreign companies appeared more frequently as patent enforcers than as accused infringers and won roughly as often as Chinese patentees. The authors also reported overall success and appeal rates similar to those observed in United States patent litigation.
These findings complicate the proposition that foreign status ordinarily places a party at a disadvantage in Chinese patent litigation. They are not, however, conclusive proof of judicial neutrality. The datasets cover different periods, courts and categories of intellectual property litigation, and some are now relatively old. Foreign companies may also be particularly selective about the cases they choose to bring, meaning that high plaintiff success rates cannot independently establish the absence of discrimination.
There is another limitation when applying this research to Infineon. Much of the cited evidence concerns foreign plaintiffs bringing claims, whereas Infineon is defending proceedings initiated by a Chinese patent holder. Plaintiff success rates do not directly answer whether foreign defendants are treated fairly. More recent research that specifically examines foreign defendants, a wider range of courts and comparable cases would help to clarify the issue.
The Infineon-Innoscience dispute across jurisdictions
The Infineon–Innoscience dispute provides a concrete, current example. Since 2024, the two companies have pursued parallel proceedings over GaN semiconductor technology in China, Germany and the United States. The resulting decisions have produced victories and setbacks for both parties. They also show why legal outcomes should be assessed in context rather than reduced to a simple national comparison.
In the United States, the International Trade Commission (ITC) issued its final determination on 7 May 2026. The Commission found a violation of section 337 of the Tariff Act in relation to claims 4 and 17 of Infineon's U.S. Patent No. 9,899,481 and imposed a limited exclusion order and cease-and-desist orders against Innoscience. At the same time, the Commission found four other asserted claims of the same patent invalid as obvious and maintained the finding of no violation concerning another Infineon patent. The decision was therefore a significant but qualified victory for Infineon, rather than a complete endorsement of its claims.
The parties emphasised different aspects of the US outcome. Infineon highlighted the infringement finding and the restrictions imposed. Innoscience, by contrast, stressed that its redesigned products fell outside the scope of the infringement finding and argued its current commercial products could continue to enter the United States. The exclusion measures remained in place after the Presidential review period concluded in July, and the parties subsequently pursued appeals before the U.S. Court of Appeals for the Federal Circuit. These competing accounts, however, illustrate the importance of distinguishing the formal decision from each company’s description of its commercial significance.
Infineon has also obtained a series of favourable rulings in Germany. On 18 June 2026, the Munich I Regional Court ruled in Infineon's favour in two further proceedings concerning a patent and a utility model, imposing restrictions on infringing products and ordering damages. On 3 July, the same court issued another infringement ruling in Infineon's favour. Infineon portrayed these decisions as part of a series of successful enforcement actions, while Innoscience responded that at least some of the German rulings concerned legacy products and did not restrict its current portfolio.
What the Chinese rulings do – and do not – show
Innoscience brought proceedings against Infineon before the Suzhou Intermediate People’s Court, alleging infringement of two Chinese GaN patents. Infineon unsuccessfully challenged the venue. The fact that the proceedings took place in Innoscience’s home city may raise questions about home-court advantage, but the venue ruling alone does not demonstrate discrimination. Establishing that claim would require evidence that the applicable jurisdictional rules were interpreted or applied differently because Infineon was a foreign defendant.
The subsequent injunction requires the same care in interpretation. After the Suzhou court restricted the sale of certain Infineon products, the SPC maintained the measures. Innoscience described this as its “final victory in China”. The published decisions, however, established that the orders were interim measures, not final judgments resolving the underlying infringement claims. That distinction does not make the orders insignificant: interim relief can have substantial commercial consequences. In July, for example, authorities required Infineon to remove several affected products from display at an electronics trade fair in Shanghai. The key distinction is between an enforceable interim measure and a final determination of liability.
Nor can the outcomes in Germany and the United States establish what the Chinese courts should decide. The proceedings involve different national patents, accused products, legal standards and procedural stages. A foreign company’s loss at the preliminary stage in China cannot, by itself, demonstrate that the judiciary is hostile to foreign patent holders. Equally, favourable rulings elsewhere do not prove that the Chinese measures were correctly or incorrectly reached.
A narrower conclusion
The significance of the dispute is therefore narrower, but more useful, than either company’s public characterisation suggests. It demonstrates how easily the result of multinational patent litigation can be converted into a broader narrative about a country's legal system. Innoscience's description of a “final victory” made the Chinese proceedings appear more conclusive than their procedural posture justified. Yet it would be equally mistaken to move to the opposite extreme and treat Infineon's successes in Germany and the United States as proof that the Chinese result must have been improperly reached.
The broader empirical evidence points towards the same caution. Existing studies do not establish that China's intellectual property system is beyond criticism, nor do they resolve the concerns identified by the USTR about technology transfer, enforcement or the treatment of foreign right holders. They do, however, make it difficult to sustain a simple assumption that foreign parties ordinarily lose Chinese patent cases because they are foreign.
More recent empirical research, particularly examining foreign defendants and developments beyond China's largest specialist courts, would be valuable before stronger conclusions can be reached. For the moment, the Infineon–Innoscience dispute illustrates a more modest principle: when a foreign company loses a patent ruling in China, the nationality of the parties should not substitute for analysis of what the court actually decided, why it decided it, and how that decision compares with the legal questions being considered elsewhere.
